Cargando…

Transthyretin amyloid cardiomyopathy disease burden quantified using (99m)Tc-pyrophosphate SPECT/CT: volumetric parameters versus SUVmax ratio at 1 and 3 hours

BACKGROUND: Various parameters derived from technetium-99m pyrophosphate ((99m)Tc-PYP) single-photon emission computed tomography (SPECT) correlate with the severity of transthyretin amyloid cardiomyopathy (ATTR-CM). However, the optimal metrics and image acquisition timing required to quantify the...

Descripción completa

Detalles Bibliográficos
Autores principales: Watanabe, Satoru, Nakajima, Kenichi, Toshima, Fumihito, Wakabayashi, Hiroshi, Yoshida, Shohei, Yoneyama, Hiroto, Komatsu, Junji, Konishi, Takahiro, Kinuya, Seigo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10682282/
https://www.ncbi.nlm.nih.gov/pubmed/37605060
http://dx.doi.org/10.1007/s12350-023-03353-w
_version_ 1785150948150083584
author Watanabe, Satoru
Nakajima, Kenichi
Toshima, Fumihito
Wakabayashi, Hiroshi
Yoshida, Shohei
Yoneyama, Hiroto
Komatsu, Junji
Konishi, Takahiro
Kinuya, Seigo
author_facet Watanabe, Satoru
Nakajima, Kenichi
Toshima, Fumihito
Wakabayashi, Hiroshi
Yoshida, Shohei
Yoneyama, Hiroto
Komatsu, Junji
Konishi, Takahiro
Kinuya, Seigo
author_sort Watanabe, Satoru
collection PubMed
description BACKGROUND: Various parameters derived from technetium-99m pyrophosphate ((99m)Tc-PYP) single-photon emission computed tomography (SPECT) correlate with the severity of transthyretin amyloid cardiomyopathy (ATTR-CM). However, the optimal metrics and image acquisition timing required to quantify the disease burden remain uncertain. METHODS AND RESULTS: We retrospectively evaluated (99m)Tc-PYP SPECT/CT images of 23 patients diagnosed with ATTR-CM using endomyocardial biopsies and/or gene tests. All patients were assessed by SPECT/CT 1 hour after (99m)Tc-PYP injection, and 13 of them were also assessed at 3 hours. We quantified (99m)Tc-PYP uptake using the volumetric parameters, cardiac PYP volume (CPV) and cardiac PYP activity (CPA). We also calculated the SUVmax ratios of myocardial SUVmax/blood pool SUVmax, myocardial SUVmax/bone SUVmax, and the SUVmax retention index. We assessed the correlations between uptake parameters and the four functional parameters associated with prognosis, namely left ventricular ejection fraction, global longitudinal strain, myocardial extracellular volume, and troponin T. CPV and CPA correlated more closely than the SUVmax ratios with the four prognostic factors. Significant correlations between volumetric parameters and prognostic factors were equivalent between 1 and 3 hours. CONCLUSIONS: The disease burden of ATTR-CM was quantified more accurately by volumetric evaluation of (99m)Tc-PYP SPECT/CT than SUVmax ratios and the performance was equivalent between 1 and 3 hours. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12350-023-03353-w.
format Online
Article
Text
id pubmed-10682282
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-106822822023-11-30 Transthyretin amyloid cardiomyopathy disease burden quantified using (99m)Tc-pyrophosphate SPECT/CT: volumetric parameters versus SUVmax ratio at 1 and 3 hours Watanabe, Satoru Nakajima, Kenichi Toshima, Fumihito Wakabayashi, Hiroshi Yoshida, Shohei Yoneyama, Hiroto Komatsu, Junji Konishi, Takahiro Kinuya, Seigo J Nucl Cardiol Original Article BACKGROUND: Various parameters derived from technetium-99m pyrophosphate ((99m)Tc-PYP) single-photon emission computed tomography (SPECT) correlate with the severity of transthyretin amyloid cardiomyopathy (ATTR-CM). However, the optimal metrics and image acquisition timing required to quantify the disease burden remain uncertain. METHODS AND RESULTS: We retrospectively evaluated (99m)Tc-PYP SPECT/CT images of 23 patients diagnosed with ATTR-CM using endomyocardial biopsies and/or gene tests. All patients were assessed by SPECT/CT 1 hour after (99m)Tc-PYP injection, and 13 of them were also assessed at 3 hours. We quantified (99m)Tc-PYP uptake using the volumetric parameters, cardiac PYP volume (CPV) and cardiac PYP activity (CPA). We also calculated the SUVmax ratios of myocardial SUVmax/blood pool SUVmax, myocardial SUVmax/bone SUVmax, and the SUVmax retention index. We assessed the correlations between uptake parameters and the four functional parameters associated with prognosis, namely left ventricular ejection fraction, global longitudinal strain, myocardial extracellular volume, and troponin T. CPV and CPA correlated more closely than the SUVmax ratios with the four prognostic factors. Significant correlations between volumetric parameters and prognostic factors were equivalent between 1 and 3 hours. CONCLUSIONS: The disease burden of ATTR-CM was quantified more accurately by volumetric evaluation of (99m)Tc-PYP SPECT/CT than SUVmax ratios and the performance was equivalent between 1 and 3 hours. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12350-023-03353-w. Springer International Publishing 2023-08-21 2023 /pmc/articles/PMC10682282/ /pubmed/37605060 http://dx.doi.org/10.1007/s12350-023-03353-w Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Article
Watanabe, Satoru
Nakajima, Kenichi
Toshima, Fumihito
Wakabayashi, Hiroshi
Yoshida, Shohei
Yoneyama, Hiroto
Komatsu, Junji
Konishi, Takahiro
Kinuya, Seigo
Transthyretin amyloid cardiomyopathy disease burden quantified using (99m)Tc-pyrophosphate SPECT/CT: volumetric parameters versus SUVmax ratio at 1 and 3 hours
title Transthyretin amyloid cardiomyopathy disease burden quantified using (99m)Tc-pyrophosphate SPECT/CT: volumetric parameters versus SUVmax ratio at 1 and 3 hours
title_full Transthyretin amyloid cardiomyopathy disease burden quantified using (99m)Tc-pyrophosphate SPECT/CT: volumetric parameters versus SUVmax ratio at 1 and 3 hours
title_fullStr Transthyretin amyloid cardiomyopathy disease burden quantified using (99m)Tc-pyrophosphate SPECT/CT: volumetric parameters versus SUVmax ratio at 1 and 3 hours
title_full_unstemmed Transthyretin amyloid cardiomyopathy disease burden quantified using (99m)Tc-pyrophosphate SPECT/CT: volumetric parameters versus SUVmax ratio at 1 and 3 hours
title_short Transthyretin amyloid cardiomyopathy disease burden quantified using (99m)Tc-pyrophosphate SPECT/CT: volumetric parameters versus SUVmax ratio at 1 and 3 hours
title_sort transthyretin amyloid cardiomyopathy disease burden quantified using (99m)tc-pyrophosphate spect/ct: volumetric parameters versus suvmax ratio at 1 and 3 hours
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10682282/
https://www.ncbi.nlm.nih.gov/pubmed/37605060
http://dx.doi.org/10.1007/s12350-023-03353-w
work_keys_str_mv AT watanabesatoru transthyretinamyloidcardiomyopathydiseaseburdenquantifiedusing99mtcpyrophosphatespectctvolumetricparametersversussuvmaxratioat1and3hours
AT nakajimakenichi transthyretinamyloidcardiomyopathydiseaseburdenquantifiedusing99mtcpyrophosphatespectctvolumetricparametersversussuvmaxratioat1and3hours
AT toshimafumihito transthyretinamyloidcardiomyopathydiseaseburdenquantifiedusing99mtcpyrophosphatespectctvolumetricparametersversussuvmaxratioat1and3hours
AT wakabayashihiroshi transthyretinamyloidcardiomyopathydiseaseburdenquantifiedusing99mtcpyrophosphatespectctvolumetricparametersversussuvmaxratioat1and3hours
AT yoshidashohei transthyretinamyloidcardiomyopathydiseaseburdenquantifiedusing99mtcpyrophosphatespectctvolumetricparametersversussuvmaxratioat1and3hours
AT yoneyamahiroto transthyretinamyloidcardiomyopathydiseaseburdenquantifiedusing99mtcpyrophosphatespectctvolumetricparametersversussuvmaxratioat1and3hours
AT komatsujunji transthyretinamyloidcardiomyopathydiseaseburdenquantifiedusing99mtcpyrophosphatespectctvolumetricparametersversussuvmaxratioat1and3hours
AT konishitakahiro transthyretinamyloidcardiomyopathydiseaseburdenquantifiedusing99mtcpyrophosphatespectctvolumetricparametersversussuvmaxratioat1and3hours
AT kinuyaseigo transthyretinamyloidcardiomyopathydiseaseburdenquantifiedusing99mtcpyrophosphatespectctvolumetricparametersversussuvmaxratioat1and3hours